经皮冠状动脉介入治疗术后患者血浆可溶性Fas因子改变及他汀类药物干预
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


The Changes and Effects of Atorvastatin on Plasma Soluble Fas in Patients After Percutaneous Coronary Intervention
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的探讨经皮冠状动脉介入治疗术后6个月再狭窄患者和术后早期患者血浆可溶性Fas的改变及短期阿托伐他汀治疗对其的影响。方法选择29例经皮冠状动脉介入治疗术后再狭窄患者和无再狭窄患者,以及20例术后早期短期应用阿托伐他汀治疗的患者,均设立正常对照组。采用酶联免疫吸附测定法检测其血浆可溶性Fas水平。结果经皮冠状动脉介入治疗术后再狭窄组血浆可溶性Fas(469±126 ng/L)显著高于正常对照组(43±9ng/L)、冠心病组(123±23 ng/L)和无再狭窄组(132±30 ng/L)(P均<0.01);冠心病组和无再狭窄组血浆可溶性Fas也高于正常对照组(P均<0.01);而冠心病组和无再狭窄组之间血浆可溶性Fas差异无显著性。择期冠状动脉介入治疗术后6 h血浆可溶性Fas水平急剧增高;术后3天对照组血浆可溶性Fas升高达最高峰,阿托伐他汀治疗组则显著降低(分别为2 036±422和1 157±268 ng/L,p<0.01);术后7天对照组仍维持在高水平,治疗组下降至最低水平(分别为1 460±266和798±111 ng/L,p<0.01)。结论经皮冠状动脉介入治疗术后再狭窄患者血浆可溶性Fas高于无再狭窄患者,血浆可溶性Fas持续增高可能成为预测再狭窄的有效指标;阿托伐他汀干预可使血浆可溶性Fas水平显著降低,可能是阿托伐他汀防治再狭窄的机制之一。

    Abstract:

    Aim To investigate the changes of plasma soluble Fas in patients with restenosis in 6 months and effects of atorvastatin on plasma soluble Fas in patients in the early stage after percutaneous coronary intervention. Methods The levels of soluble Fas in plasma of patients were examined by means of enzyme-linked immunosorbent assay in 13 patients with restenosis,in 16 patients without restenosis in 6 months after percutaneous coronary intervention,in 20 patients with coronary artery disease,in 20 healthy without stenosis in coronary angiography,and in 20 patients treated with selective percutaneous coronary intervention and with or atorvastatin in prior percutaneous coronary intervention,6 h,24 h,3 d and 7 d after percutaneous coronary intervention. Results The levels of soluble Fas in patients with restenosis 6 months after percutaneous coronary intervention were significantly higher than those patients without restenosis,those patients with coronary artery disease and those patients without stenosis in coronary angiography(469±126 vs 132±30,123±23,43±9 ng/L,respectively,all p<0.01).The levels of soluble Fas were also significantly higher in patients without restenosis after percutaneous coronary intervention and in patients with coronary artery disease than those patients without stenosis in coronary angiography(all p<0.01).The levels of soluble Fas were rapidly increased in patients 6h after selective percutaneous coronary intervention,reached its peak after 3 d,and remained very high after 7 d. The levels of soluble Fas were significantly decreased in patients 3 d and 7 d after treatment with atorvastatin than those patients without atorvastatin(from 2 036±422 to 1 157±268 ng/L,and 1 460±266 to 798±111 ng/L,respectively,all p<0.01). Conclusions The levels of soluble Fas were significantly higher in patients with restenosis after percutaneous coronary intervention than those patients without restenosis.Persist increment of soluble Fas may act as the predictors of restenosis after percutaneous coronary intervention.The levels of soluble Fas significantly decreased after treatment of atorvastatin,which may be one of mechanisms of statins preventing restenosis that.

    参考文献
    相似文献
    引证文献
引用本文

许宜冠,周胜华,沈向前,祁述善,刘启明,李旭平.经皮冠状动脉介入治疗术后患者血浆可溶性Fas因子改变及他汀类药物干预[J].中国动脉硬化杂志,2006,14(4):343~346.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2005-05-17
  • 最后修改日期:2006-02-06
  • 录用日期:
  • 在线发布日期: